Free Trial

VYNE Therapeutics (VYNE) Competitors

VYNE Therapeutics logo
$1.46 +0.12 (+8.96%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.45 -0.01 (-0.96%)
As of 07/25/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE vs. PYXS, BMEA, INCR, PMVP, GNTA, QNTM, TELO, CUE, AVTX, and IRD

Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), PMV Pharmaceuticals (PMVP), Genenta Science (GNTA), Quantum Biopharma (QNTM), Telomir Pharmaceuticals (TELO), Cue Biopharma (CUE), Avalo Therapeutics (AVTX), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry.

VYNE Therapeutics vs. Its Competitors

Pyxis Oncology (NASDAQ:PYXS) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

In the previous week, Pyxis Oncology had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.87 beat Pyxis Oncology's score of 1.82 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Pyxis Oncology Very Positive
VYNE Therapeutics Very Positive

Pyxis Oncology has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 10.6% of Pyxis Oncology shares are owned by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

VYNE Therapeutics has lower revenue, but higher earnings than Pyxis Oncology. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pyxis Oncology$16.15M4.79-$77.33M-$1.59-0.79
VYNE Therapeutics$605K36.71-$39.83M-$0.99-1.47

Pyxis Oncology presently has a consensus target price of $9.00, indicating a potential upside of 620.00%. VYNE Therapeutics has a consensus target price of $6.25, indicating a potential upside of 328.08%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pyxis Oncology
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
VYNE Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Pyxis Oncology has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. Pyxis Oncology's return on equity of -57.49% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pyxis OncologyN/A -57.49% -45.17%
VYNE Therapeutics -6,974.55%-71.89%-58.94%

Summary

Pyxis Oncology beats VYNE Therapeutics on 9 of the 16 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYNE vs. The Competition

MetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$20.38M$2.50B$5.70B$9.50B
Dividend YieldN/A1.75%4.60%4.01%
P/E Ratio-1.479.0528.1020.05
Price / Sales36.71592.30429.3789.38
Price / CashN/A165.2136.2258.56
Price / Book0.415.168.665.87
Net Income-$39.83M$30.99M$3.25B$258.55M
7 Day Performance25.86%7.74%4.22%3.73%
1 Month Performance-9.88%16.27%10.51%11.75%
1 Year Performance-30.14%-1.88%34.40%18.03%

VYNE Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYNE
VYNE Therapeutics
2.9491 of 5 stars
$1.46
+9.0%
$6.25
+328.1%
-30.5%$20.38M$605K-1.4730Positive News
PYXS
Pyxis Oncology
2.4244 of 5 stars
$1.13
flat
$9.00
+696.5%
-67.5%$70M$16.15M-0.7160
BMEA
Biomea Fusion
3.2788 of 5 stars
$1.83
-1.1%
$20.10
+998.4%
-66.5%$69.51MN/A-0.5250Upcoming Earnings
INCR
InterCure
0.6609 of 5 stars
$1.55
+2.0%
N/A-36.3%$69.27M$66.28M0.00350Positive News
PMVP
PMV Pharmaceuticals
3.1648 of 5 stars
$1.34
+0.8%
$5.50
+310.4%
-14.5%$69.10MN/A-1.1450News Coverage
GNTA
Genenta Science
2.7341 of 5 stars
$3.77
-0.1%
$25.00
+564.0%
-9.5%$68.95MN/A0.007
QNTM
Quantum Biopharma
N/A$23.71
+1.5%
N/AN/A$67.95MN/A-1.48N/A
TELO
Telomir Pharmaceuticals
2.9219 of 5 stars
$2.21
-3.1%
$15.00
+578.7%
-44.8%$67.86MN/A-5.261News Coverage
Gap Down
High Trading Volume
CUE
Cue Biopharma
4.0437 of 5 stars
$0.88
-1.9%
$3.00
+239.8%
+25.5%$67.82M$9.29M-1.3260Positive News
AVTX
Avalo Therapeutics
3.5396 of 5 stars
$6.73
+7.7%
$30.00
+345.8%
-42.5%$67.67M$440K0.0040News Coverage
Positive News
IRD
Opus Genetics
1.6456 of 5 stars
$1.19
+5.3%
$7.33
+516.2%
N/A$67.42M$13.65M-0.5714

Related Companies and Tools


This page (NASDAQ:VYNE) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners